GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter to...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter to settle lawsuits and regulatory fines related to past sales practices. The sum outstrips Pfizer's (PFE) 2009 payment of $2.3B and relates mostly to practices between 1997 and 2004, including those around antidepressants Paxil and Wellbutrin and former diabetes blockbuster Avandia.